Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Elevance Health (ELV)

Elevance Health Q1 EPS rises 15.5% to $9.59 and raises 2024 EPS outlook

Positive Impact 4 of 5 earnings Written later

Elevance Health reported first quarter 2024 results on April 18, 2024, with operating revenue of $42.3 billion, up 0.9% from a year earlier, and diluted EPS of $9.59, up 15.5%. The company raised its full-year 2024 guidance to diluted EPS greater than $34.05 and adjusted diluted EPS greater than $37.20, which signals stronger expected earnings for shareholders.

Key points

  • Q1 2024 diluted EPS was $9.59, up 15.5%; adjusted diluted EPS was $10.64, up 12.5%
  • Operating revenue was $42.3 billion, up 0.9%; total operating margin was 7.1%, up 30 basis points
  • Full-year 2024 diluted EPS guidance raised to greater than $34.05; adjusted diluted EPS guidance raised to greater than $37.20
  • Repurchased 1.1 million shares for $566 million in Q1; quarterly dividend of $1.63 per share declared, payable June 25, 2024

The filing

CompanyElevance Health (ELV)
Form8-K, current report
Filed with the SECApr 18, 2024, 6:07 AM ET
Accession number0001193125-24-099824

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 18, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.